Global Pheochromocytoma Market – Industry Trends and Forecast to 2028

Market Analysis and Insights : Global Pheochromocytoma Market

The pheochromocytoma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 3.45% in the forecast period of 2021 to 2028 and is expected to reach USD 3,951.34 million by 2028. The increase in prevalence of pheochromocytoma among population across the globe and rise in development of treatments are escalating the growth of pheochromocytoma market.

Pheochromocytoma refers to a rare type of hormone-secreting tumor which is seen in the adrenal gland. This tumor is mainly benign which does not cause cancer but 5% of adrenal gland tumors are pheochromocytoma. Only 10% of these cases develop to become cancerous. There is secretion of catecholamine hormones in this adrenal gland tumor which results in either episodic or persistent high blood pressure. It is considered similar to adrenal paraganglioma. The condition arises from the chromaffin cells and approximately 25%-35% occur due to genetic disruptions or mutations to certain genes.

The increased rate in the cases of pheochromocytoma among population globally and the rise in research and development activities to enhance specific treatments for the condition are the major factors driving the pheochromocytoma market. The rise in the number of drugs in clinical trials and increase in the investment by leading key players to develop specific drugs to treat the condition accelerates the pheochromocytoma market growth. The growing expertise in gene therapy and the need for cost-effective treatment options also influence the pheochromocytoma market. The increase in number of rare tumors and technological advancement in diagnosis also boosts the pheochromocytoma market growth. Additionally, the rise in healthcare expenditure and unhealthy lifestyle such as smoking and drinking positively affect the pheochromocytoma market. Furthermore, new product offerings, penetration of the market in developing nations and emerging economies extend profitable opportunities to the pheochromocytoma market players in the forecast period of 2021 to 2028.   

On the other hand, implementation of stringent regulatory norms and policies and lack of availability of specific drugs are expected to obstruct the pheochromocytoma market growth. Lack of awareness of the disease among people is expected to challenge the pheochromocytoma market in the forecast period of 2021-2028.

This pheochromocytoma market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on pheochromocytoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Pheochromocytoma Market Scope and Market Size

The pheochromocytoma market is segmented on the basis of diagnosis, treatment and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. 

• On the basis of diagnosis, the pheochromocytoma market is segmented into laboratory tests, imaging tests and genetic testing.
• On the basis of treatment, the pheochromocytoma market is segmented into medication, surgery, radionuclide treatment and others. Medication is further segmented into alpha blockers and beta blockers.
• On the basis of end users, the pheochromocytoma market is segmented into hospitals, clinics, research and academic institutes and others.

Global Pheochromocytoma Market Country Level Analysis

Global pheochromocytoma market is analyzed and market size insights and trends are provided by country, diagnosis, treatment and end users as referenced above.      

The countries covered in the pheochromocytoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the pheochromocytoma market because of the rising incidences of pheochromocytoma, availability of cost-effective treatment options, increase in technological advancements and presence of prominent pharmaceutical manufacturers in the region. Asia-Pacific is estimated to grow in the forecast period of 2021-2028 due to the improvement in healthcare infrastructure and rise in the number of patients suffering from adrenal gland tumors including pheochromocytoma.

The country section of the pheochromocytoma market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The pheochromocytoma market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for pheochromocytoma market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pheochromocytoma market. The data is available for historic period 2010-2019.

Competitive Landscape and Pheochromocytoma Market Share Analysis

The pheochromocytoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to pheochromocytoma market.

The major players covered in the pheochromocytoma market report are MediaPharma s.r.l., Pfizer Inc., Lantheus Holdings, Inc, Bausch Health Companies Inc., Exelixis, Inc, Teva Pharmaceutical Industries Ltd., Zydus Cadila, Curium Pharma, Jubilant Cadista, AstraZeneca, Mylan N.V., Apotex Inc., Dr. Reddy’s Laboratories Ltd., LUPIN, Glenmark, Endo International plc, Eisai Co., Ltd., Bristol-Myers Squibb Company, AbbVie Inc., DAIICHI SANKYO COMPANY, LIMITED, Bayer AG, GENERAL ELECTRIC COMPANY among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-58787